Skip to main
CTSO
CTSO logo

CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents (CTSO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

CytoSorbents Corp has demonstrated a 10% year-over-year increase in product revenues, achieving $9.5 million with gross margins exceeding 70%, indicating improved operational efficiency. The company is experiencing notable revenue growth through its distributor network, particularly outside Germany, where global distribution partner sales rose by 14.4% year-over-year. Additionally, management's strategic focus on advancing innovations like DrugSorb-ATR and the anticipation of returning Germany to growth by 2026 bolster the company's positive outlook.

Bears say

CytoSorbents Corp is experiencing a decline in revenue growth, particularly in Germany, which is its most significant market. Revenue expectations for 2025 and 2026 have been revised downward to $38.2 million and $40.8 million, respectively, reflecting a decrease from previous forecasts. This continuous underperformance in Germany has led to a generally negative outlook for the company's financial performance, further supported by an adjustment in the projected price target.

CytoSorbents (CTSO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytoSorbents (CTSO) Forecast

Analysts have given CytoSorbents (CTSO) a Buy based on their latest research and market trends.

According to 2 analysts, CytoSorbents (CTSO) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytoSorbents (CTSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.